Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

3(60.0%)

N/A

1(20.0%)

Phase 2

1(20.0%)

5Total

Phase 4(3)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT00504712Phase 4Completed

Testosterone for Peripheral Vascular Disease

Role: lead

NCT00189852Not ApplicableCompleted

Supporting Care and Independence at Home

Role: lead

NCT00189878Phase 2Terminated

A Study of the Use of Methotrexate in the Treatment of Chronic Idiopathic Urticaria

Role: lead

NCT00349362Phase 4Completed

Testosterone for Men With Insulin Treated Type 2 Diabetes

Role: lead

NCT00355537Phase 4Completed

Testosterone Replacement in Diabetes With Vascular Disease (Version 2)

Role: lead

All 5 trials loaded